Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer
Dateline City:
KENILWORTH, N.J. & INDIANAPOLIS
Combinations of KEYTRUDA® (pembrolizumab) with Alimta® (pemetrexed), Cyramza® (ramucirumab), or necitumumab to be explored
KENILWORTH, N.J. & INDIANAPOLIS--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly
and Company (NYSE:LLY) announced today an oncology clinical trial
collaboration to evaluate the safety, tolerability and efficacy of
KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination
with Lilly compounds in multiple clinical trials:
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Justin Holko, 908-740-1879orLillyEli Lilly and CompanyKeri McGrath, 317-277-3768Communications Managermcgrath_happeks@lilly.com
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: LLY Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news